Suzaan Marais

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6248127/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infectious Diseases, The, 2010, 10, 803-812.	9.1	659
2	Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19013-19017.	7.1	174
3	Neurologic Manifestations of Paradoxical Tuberculosisâ€Associated Immune Reconstitution Inflammatory Syndrome: A Case Series. Clinical Infectious Diseases, 2009, 48, e96-e107.	5.8	163
4	Frequency, Severity, and Prediction of Tuberculous Meningitis Immune Reconstitution Inflammatory Syndrome. Clinical Infectious Diseases, 2013, 56, 450-460.	5.8	162
5	Diagnosis of tuberculous meningitis: clinical and laboratory parameters. International Journal of Infectious Diseases, 2007, 11, 348-354.	3.3	96
6	Presentation and Outcome of Tuberculous Meningitis in a High HIV Prevalence Setting. PLoS ONE, 2011, 6, e20077.	2.5	96
7	Management of the Immune Reconstitution Inflammatory Syndrome. Current HIV/AIDS Reports, 2012, 9, 238-250.	3.1	87
8	Central Nervous System Immune Reconstitution Inflammatory Syndrome. Current Infectious Disease Reports, 2013, 15, 583-593.	3.0	83
9	HIV–tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling. Nature Communications, 2015, 6, 8451.	12.8	81
10	Improving the microbiological diagnosis of tuberculous meningitis: A prospective, international, multicentre comparison of conventional and modified Ziehl–Neelsen stain, GeneXpert, and culture of cerebrospinal fluid. Journal of Infection, 2018, 77, 509-515.	3.3	81
11	Neutrophil-Associated Central Nervous System Inflammation in Tuberculous Meningitis Immune Reconstitution Inflammatory Syndrome. Clinical Infectious Diseases, 2014, 59, 1638-1647.	5.8	68
12	Management of patients with the immune reconstitution inflammatory syndrome. Current HIV/AIDS Reports, 2009, 6, 162-171.	3.1	62
13	Standardized methods for enhanced quality and comparability of tuberculous meningitis studies. Clinical Infectious Diseases, 2017, 64, ciw757.	5.8	61
14	HIV-associated tuberculous meningitis – diagnostic and therapeutic challenges. Tuberculosis, 2010, 90, 367-374.	1.9	60
15	Central nervous system disorders after starting antiretroviral therapy in South Africa. Aids, 2010, 24, 2871-2876.	2.2	60
16	Inflammasome activation underlies central nervous system deterioration in HIV-associated tuberculosis. Journal of Infectious Diseases, 2017, 215, jiw561.	4.0	57
17	Spinal Tuberculosis: Clinicoradiological Findings in 274 Patients. Clinical Infectious Diseases, 2018, 67, 89-98.	5.8	42
18	Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa. South African Medical Journal. 2012, 102, 506.	0.6	32

SUZAAN MARAIS

#	Article	IF	CITATIONS
19	Barriers to Initiation of Antiretrovirals during Antituberculosis Therapy in Africa. PLoS ONE, 2011, 6, e19484.	2.5	29
20	T cell derived HIV-1 is present in the CSF in the face of suppressive antiretroviral therapy. PLoS Pathogens, 2021, 17, e1009871.	4.7	25
21	Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors. BMC Infectious Diseases, 2010, 10, 83.	2.9	24
22	Interleukin-17 mediated differences in the pathogenesis of HIV-1-associated tuberculous and cryptococcal meningitis. Aids, 2015, 30, 1.	2.2	19
23	Management of intracranial tuberculous mass lesions: how long should we treat for?. Wellcome Open Research, 0, 4, 158.	1.8	16
24	SARS-CoV-2 Encephalitis Presenting as a Clinical Cerebellar Syndrome. Neurology, 2021, 97, 27-29.	1.1	14
25	Management of intracranial tuberculous mass lesions: how long should we treat for?. Wellcome Open Research, 2019, 4, 158.	1.8	12
26	High dose oral rifampicin to improve survival from adult tuberculous meningitis: A randomised placebo-controlled double-blinded phase III trial (the HARVEST study). Wellcome Open Research, 2019, 4, 190.	1.8	11
27	Management Issues in Myasthenia Gravis Patients Living With HIV: A Case Series and Literature Review. Frontiers in Neurology, 2020, 11, 775.	2.4	10
28	Assessment at Antiretroviral Clinics during TB Treatment Reduces Loss to Follow-Up among HIV-Infected Patients. PLoS ONE, 2012, 7, e37634.	2.5	8
29	International Survey Reveals Opportunities to Improve Tuberculous Meningitis Management and the Need for Standardized Guidelines. Open Forum Infectious Diseases, 2020, 7, ofaa445.	0.9	6
30	High dose oral rifampicin to improve survival from adult tuberculous meningitis: A randomised placebo-controlled double-blinded phase III trial (the HARVEST study). Wellcome Open Research, 2019, 4, 190.	1.8	6
31	The diagnosis and medical management of tuberculous meningitis in adults. South African Medical Journal, 2014, 104, 895.	0.6	5
32	Posttubercular syringomyelia in HIV-infected patients: A report of 10 cases and literature review. Journal of the Neurological Sciences, 2018, 395, 54-61.	0.6	4
33	Management of intracranial tuberculous mass lesions: how long should we treat for?. Wellcome Open Research, 0, 4, 158.	1.8	3
34	Host transcriptomic signatures of tuberculosis can predict immune reconstitution inflammatory syndrome in HIV patients. European Journal of Immunology, 2022, , .	2.9	3
35	Tuberculosis in Myasthenia Gravis patients on immunosuppressive therapy in a high-risk area: Implications for preventative therapy. Journal of the Neurological Sciences, 2021, 425, 117447.	0.6	2

36 Immune reconstitution inflammatory syndrome (IRIS). , 0, , 669-675.

#	Article	IF	CITATIONS
37	Neurological TB in HIV. , 2019, , 295-334.		1
38	Are the Present Doses of Anti Tubercular Drugs Adequate for Severe Disease?. EBioMedicine, 2015, 2, 1572-1573.	6.1	0
39	A comparative study of human T-cell lymphotropic virus-associated myelopathy in HIV-positive and HIV-negative patients in KwaZulu-Natal. Southern African Journal of HIV Medicine, 2017, 18, .	0.9	0